Last reviewed · How we verify
Standard bismuth quadruple therapy
Bismuth subsalicylate has antimicrobial properties that help treat and prevent ulcers and gastroesophageal reflux disease (GERD).
Bismuth subsalicylate has antimicrobial properties that help treat and prevent ulcers and gastroesophageal reflux disease (GERD). Used for Treatment of Helicobacter pylori infection in patients with peptic ulcer disease, Treatment of gastroesophageal reflux disease (GERD).
At a glance
| Generic name | Standard bismuth quadruple therapy |
|---|---|
| Sponsor | VA Office of Research and Development |
| Drug class | Antimicrobial |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Bismuth subsalicylate works by reducing the growth of bacteria and other microorganisms in the stomach and intestines, which can cause ulcers and GERD. It also has anti-inflammatory properties that help reduce stomach acid and heal ulcers.
Approved indications
- Treatment of Helicobacter pylori infection in patients with peptic ulcer disease
- Treatment of gastroesophageal reflux disease (GERD)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
Key clinical trials
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy (PHASE4)
- The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication (EARLY_PHASE1)
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication (PHASE4)
- Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication (PHASE4)
- H. Pylori Screen-and-treat Study in a Population of Young Adults
- Bismuth Quadruple Therapy Versus Standard Triple Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: